The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

At the ITF Masters event in Bedford, NS, last month, the Canadians cleaned up by winning almost every title at the Atlantic ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

A new government program will give pregnant mothers and newborns free access to RSV vaccines, a move that is expected to ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD).